Physician profile
David Joseph Sosnowik
NPI 1053378075
$3,368.44
in general payments reported to CMS, 2019-2025
33 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $461 · 2021: $785 · 2022: $485 · 2023: $590 · 2024: $502 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $363.32 | 2019-2022 | |
| Abbvie INC. | $341.71 | 2019-2024 | Skyrizi, Rinvoq |
| Qol Medical, LLC | $318.24 | 2020-2024 | Sucraid, Sucraid |
| Glaxosmithkline, LLC. | $270.97 | 2021-2023 | Shingrix, Arexvy |
| Janssen Biotech, INC. | $240.02 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.79 | 2020-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $167.23 | 2020-2025 | Entyvio, Vpriv |
| Novo Nordisk INC | $155.02 | 2021-2024 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $150.00 | 2023 | |
| Merck Sharp & Dohme LLC | $104.86 | 2020-2024 | Gardasil 9, Gardasil |
| Braintree Laboratories, INC. | $104.72 | 2019-2024 | Sutab, Suflave |
| Celgene Corporation | $68.20 | 2023-2024 | Zeposia |
| Astrazeneca Pharmaceuticals LP | $67.25 | 2024 | Airsupra, Farxiga |
| Daiichi Sankyo INC. | $64.10 | 2022-2024 | Injectafer |
| Phathom Pharmaceuticals, INC. | $63.80 | 2023-2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $62.64 | 2021-2022 | |
| Shire North American Group INC | $60.85 | 2019 | |
| Ferring Pharmaceuticals INC. | $60.12 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $59.15 | 2019-2021 | |
| Pfizer INC. | $56.82 | 2023-2024 | |
| Alfasigma USA, INC. | $53.56 | 2020-2021 | |
| Exact Sciences Corporation | $47.93 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $43.40 | 2023 | Mounjaro |
| Intra-Sana Laboratories | $39.26 | 2021-2022 | |
| Celltrion USA INC. | $35.43 | 2024-2025 | Vegzelma |
| Glycomark, INC. | $31.04 | 2019 | |
| Genzyme Corporation | $30.70 | 2024 | |
| Ironwood Pharmaceuticals, INC | $21.80 | 2020 | |
| Alnylam Pharmaceuticals INC. | $21.11 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.04 | 2020 | |
| Shield Therapeutics INC | $16.71 | 2024 | |
| Allergan, INC. | $16.08 | 2019 | |
| Medline Industries LP | $15.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Sosnowik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.